Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of Göttingen
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03243461CT.gov International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) | — | Unknown | — | — | — |
NCT01861990CT.gov Valproic Acid in Childhood Progressive Brain Tumors | — | Withdrawn | — | — | — |
NCT00879437CT.gov Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Astrocytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Valproic Acid (this asset) | University of Göttingen | P3 | B · 61 |
| Irinotecan | City of Hope Medical Center | P2/3 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| (+)-Vincristine | Novartis Pharmaceuticals | P2/3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P1/2 | BB |
| Carboplatin | Oliver Jonas | P2 | BB |
| Temsirolimus | Andrew B Lassman, MD | P1/2 | B |
| Trametinib | National Cancer Institute (NCI) | P4 | B |
| Ziv-Aflibercept | National Cancer Institute (NCI) | P2 | B |
+42 more in the Anaplastic Astrocytoma cohort
Other indications for Valproic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar Disorder | — | P4 | BBB · 73 |
| Epilepsy | — | P4 | BBB · 73 |
| Bipolar I Disorder | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Valproic Acid in Anaplastic Astrocytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/valproic-acid-anaplastic-astrocytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →